CurrentRheuma — Fibromyalgia & musculoskeletal pain

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews

2026-11-04T23:58:28.520Z

Research article · BMJ, 2023. Pain (0–100), efficacious comparisons with moderate certainty evidence (SNRIs vs placebo) — SNRIs vs Placebo: mean difference -5.3 (95% CI -7.3 to -3.3); back pain

A national media mass campaign improves beliefs and behaviours about low back pain in the general population and in general practitioners

2026-11-04T23:42:37.367Z

Cross-sectional study · Joint Bone Spine, 2023. General population adhering to "One should maintain physical activity" when dealing with LBP: Before 56% · 6 months 74% · 18 months 75%

Evaluation of the efficacy, in terms of pain and disability, of a functional restoration programme in patients with chronic low back pain according to the presence of Modic 1 discopathy

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2023. Functional Restoration Programmes (FRP) success, one month: Without MD1 49.1% · MD1 39.2%

Sleep and Sleep Complaints in Juvenile Fibromyalgia Syndrome

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2023. Sleep quality: nonrestorative sleep and PSG sleep parameters vs age-matched healthy controls — JFS vs Healthy controls: Sleep period time (significantly longer in JFS); P = 0.004

Disentangling the relationship between depression and chronic widespread pain: A Mendelian randomisation study

2026-11-04T23:02:07.938Z

Research article · Semin Arthritis Rheum, 2023. Risk of CWP per doubling in odds of genetic liability to depression: OR (95% CrI 1.003-1.005); p = 7.3 × 10-5 that the causal model is a better fit than non-causal model 1.004

Looking at fibromyalgia differently – An observational study of the meaning and consequences of fibromyalgia as a dimensional disorder

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2022. Clinical and demographic variables across PSD scale score groups; overlap between FM- (PSD 8-11) and FM+ (PSD 12-18): Clinical and demographic variables became more abnormal with increasing PSD score groups; changes across PSD categories linear and large

The concomitant diagnosis of fibromyalgia and connective tissue disorders: A systematic review

2026-11-04T23:02:07.938Z

Meta-analysis · Semin Arthritis Rheum, 2022. Prevalence of concomitant diagnosis: Concomitant hEDS/HSD and FMS 68%-88.9%

Oxidative stress involves phenotype modulation of morbid soreness symptoms in fibromyalgia

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Prevalence of soreness symptoms in FM: FM 92.2%

Mind the Mood: Momentary Depression and Anxiety Moderate the Correspondence Between Subjective and Objective Cognitive Functioning in Fibromyalgia

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2023. Momentary SCD positively associated with mean reaction time P < 0.001

Predictors of Pain Reduction Among Fibromyalgia Patients Using Medical Cannabis: A Long‐Term Prospective Cohort Study

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Mediation of pain intensity reduction: Reductions in pain intensity partly explained by concurrent reductions in sleep problems P < 0.001

Prevalence of Fibromyalgia Syndrome in Active‐Duty Military Personnel

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. Prevalence of FM: PTSD 10.8% · Without PTSD 0.8% · PTSD treatment trials 39.7%

Recruitment and Retention Strategies for Underrepresented Populations and Adults With Arthritis in Behavioral Interventions: A Scoping Review

2026-11-04T22:50:06.138Z

Research article · Arthritis Care Res (Hoboken), 2023. Frequent recruitment strategies: race- or community-matched team members, flyers and information sessions in areas frequented by the population, targeted emails/mailings, word of mouth referrals

Prevalence of non-coeliac gluten sensitivity and assessment of the response to gluten-free diet in a cohort of patients with fibromyalgia

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. non-coeliac gluten sensitivity (NCGS) prevalence: NCGS prevalence 5.6%

Adverse effects of the COVID-19 pandemic on fibromyalgia patients in Germany: a longitudinal investigation including pre-pandemic data of pain and health-related outcomes

2026-11-04T19:02:33.172Z

Cohort study · Clin Exp Rheumatol, 2023. Self-perceived and longitudinal changes during the pandemic, T1-T2: Significant self-perceived worsening of pain, depressive mood, anxiety and reduced physical activity due to the pandemic

Association of fibromyalgia with cancerous and non-cancerous gastrointestinal comorbidities: a cross-sectional study

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Fibromyalgia vs Controls: OR (IBS) 4.61 (95% CI 4.09-5.2); p<0.001

Blood transcriptome and machine learning identified the crosstalk between COVID-19 and fibromyalgia: a preliminary study

2026-11-04T19:02:33.172Z

Mechanistic study · Clin Exp Rheumatol, 2022. differentially expressed genes (DEGs) identified in the FM dataset 2505

Brain morphometry changes with fatigue severity in fibromyalgia

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2022. After adjusting for anxiety and depression, decreased bilateral thalamic volumes associated with higher fatigue severity

Design and validation of a predictive model for determining the risk of developing fibromyalgia

2026-11-04T19:02:33.172Z

Cohort study · Clin Exp Rheumatol, 2022. Predictive capacity of the final model, adjusted by Bootstrapping: Predictive capacity adjusted by Bootstrapping 0.972 (95% CI: 0.955-0.986)

Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2022. PASS threshold: FIQR ≤58; AUC 0.819 · FASmod ≤23; AUC 0.805 · PSD ≤16; AUC 0.773

Exploring the prevalence and clinical impact of fibromyalgia syndrome in patients with shoulder diseases: a cross-sectional study

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2023. Prevalence of FM syndrome (2016 criteria): FM criteria positive 12 (5.97%)

Gender differences in the revised Fibromyalgia Impact Questionnaire: a pilot study

2026-11-04T19:02:33.172Z

Case-control study · Clin Exp Rheumatol, 2023. FIQR scores (univariate analysis): Total FIQR scores significantly higher in females

Outcome of small fibers pathology in fibromyalgia: a real life longitudinal observational study.

2026-11-04T19:02:33.172Z

Cohort study · Clin Exp Rheumatol, 2022. IENFD, T0 and T1 (18 months): IENFD normal at T0 10

Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study

2026-11-04T19:02:33.172Z

Randomized controlled trial · Clin Exp Rheumatol, 2023. WPI, time-integrated AUC, 24 weeks after randomisation — Group 2 vs Group 1; p=0.048; AUC values of the WPI scores steadily decreased in Group 2

The efficacy of a brief acceptance-based group intervention in a sample of female patients with fibromyalgia and comorbid obesity: a randomised controlled trial

2026-11-04T19:02:33.172Z

Randomized controlled trial · Clin Exp Rheumatol, 2023. Pain acceptance, after the interventions (T1): Significant improvement with acceptance-based treatment (ABT)+TAU vs TAU

The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod

2026-11-04T19:02:33.172Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Correlations between severity indices: FIQR vs PSD correlation (r) 0.714

Effectiveness of patient education as a stand-alone intervention for patients with chronic widespread pain and fibromyalgia: a systematic review and meta-analysis of randomized trials

2026-11-04T19:00:51.860Z

Meta-analysis · Scand J Rheumatol, 2023. Patients' global assessment — Patient education vs Usual care, no intervention, or waiting list: SMD 0.79 (95% CI 0.13 to 1.46)

Pain extent is associated with Central Sensitization Inventory but not widespread pressure pain sensitivity or psychological variables in women with fibromyalgia

2026-11-04T19:00:51.860Z

Cross-sectional study · Scand J Rheumatol, 2022. Correlates of pain extent: Correlation of pain extent with age (r) 0.17

Functional Connectivity and Structural Signatures of the Visual Cortical System in Fibromyalgia: A Magnetic Resonance Imaging Study

2026-11-04T18:58:37.862Z

Cross-sectional study · J Rheumatol, 2023. FM: increased FCs within visual networks; FC between visual medial network and right lingual gyrus positively correlated with Fibromyalgia Impact Questionnaire (FIQ) score

Exercise-based interventions on sleep quality in patients with fibromyalgia syndrome: An umbrella and mapping review with meta-analysis

2026-11-04T18:56:42.207Z

Meta-analysis · Semin Arthritis Rheum, 2023. Sleep quality — EBIs vs Minimal intervention, no intervention or usual care: SMD -0.46 (CI -0.69 to -0.23); moderate statistically significant effect

The value of inquiring patients about local discomfort during blood pressure measurement for fibromyalgia detection. A cross-sectional study

2026-11-04T18:56:42.207Z

Cross-sectional study · Semin Arthritis Rheum, 2023. Diagnostic accuracy for FM (2016 Wolfe criteria) in women: "Much" local pain: sensitivity 23%; specificity 96%

Brain morphometric changes in fibromyalgia and the impact of psychometric and clinical factors: a volumetric and diffusion-tensor imaging study

2026-11-04T18:52:31.576Z

Cross-sectional study · Arthritis Res Ther, 2023. Significantly decreased GM volumes in bilateral middle temporal gyrus (MTG), parahippocampal gyrus, left dorsal anterior cingulate cortex (dACC), right putamen, right caudate nucleus and left dorsolateral prefrontal cortex (DLPFC)

Association of Calcaneal Bone Marrow Lesions and Plantar Fascia Imaging Biomarkers With Chronic Plantar Heel Pain: A Case–Control Study

2026-11-04T18:49:03.987Z

Case-control study · Arthritis Care Res (Hoboken), 2022. Imaging biomarkers independently associated with CPHP — CPHP vs Controls: OR 1.03 mm2 (95% CI 1.02-1.05); plantar calcaneal BML size

Identifying Long‐Term Trajectories of Foot Pain Severity and Potential Prognostic Factors: A Population‐Based Cohort Study

2026-11-04T18:49:03.987Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Foot pain severity trajectories (latent class growth analysis (LCGA), 4-trajectory model), 7 years: Mild, improving 37% · Moderate, improving 33% · Moderate-severe, persistent 24% · Severe, persistent 6%

Comparison of health-care utilization, costs and health-related quality of life across the subgroups defined by the Keele STarT MSK Tool

2026-11-04T18:44:40.719Z

Cohort study · Rheumatology (Oxford), 2022. Total health-care (NHS and private) costs, 6 months: Low-risk mean 132.92 ± 167.88 £ · Medium-risk mean 279.32 ± 462.98 £ · High-risk mean 476.07 ± 716.44 £

Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

2026-11-04T18:43:51.823Z

Research article · Lancet Rheumatol, 2023. 2020: Prevalent cases, global, 2020 619 million (95% UI 554-694)

Prevalence of survey-based criteria for fibromyalgia and impact on hospital burden: a 7 year follow-up study from an outpatient clinic

2026-11-04T15:38:38.121Z

Cohort study · Scand J Rheumatol, 2022. Fulfilment of survey-based FM criteria, enrolment: FM 90 (36%)

The validity of the Danish version of the Fibromyalgia Impact Questionnaire – Revised applied in a clinical setting: a Rasch analysis

2026-11-04T15:38:38.121Z

Diagnostic or prognostic study · Scand J Rheumatol, 2022. Psychometric properties of the Danish FIQR (Rasch analysis): Multiple threshold disordering in the 0-10 category rating scale

Effectiveness of non-pharmacological interventions for fibromyalgia and quality of review methods: an overview of Cochrane Reviews

2026-11-04T15:35:22.665Z

Randomized controlled trial · Semin Arthritis Rheum, 2023. end of the intervention: Low certainty evidence of clinically relevant positive effects of aerobic and mixed exercise training and cognitive behavioural therapies (CBTs) at reducing mobility difficulties

Fibromyalgia and mortality: a systematic review and meta-analysis

2026-11-04T15:32:17.112Z

Meta-analysis · RMD Open, 2023. All-cause mortality in fibromyalgia: Increased HR for all-cause mortality HR 1.27, 95% CI 1.04 to 1.51

Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double‐Blind, Placebo‐Controlled Trial

2026-11-04T15:28:30.608Z

Randomized controlled trial · Arthritis Care Res (Hoboken), 2023. Daily pain, LS mean change from baseline, week 14: TNX-102 SL LS mean change -1.9 (95% CI -2.1, -1.7) · Placebo LS mean change -1.5 (95% CI -1.7, -1.3)

Patterns of Imaging Requests By General Practitioners for People With Musculoskeletal Complaints: An Analysis From a Primary Care Database

2026-11-04T15:28:30.608Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Proportion with imaging requested, by body region: Shoulder 49% · Knee 43% · Neck 34% · Low back 26%

Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort

2026-11-04T15:23:59.664Z

Cohort study · Rheumatology (Oxford), 2022. Poor 89 (29%) · Average 190 (61.4%) · Excellent 30 (9.7%)

The bidirectional association between chronic musculoskeletal pain and sleep-related problems: a systematic review and meta-analysis

2026-11-04T15:23:59.664Z

Meta-analysis · Rheumatology (Oxford), 2023. Incidence of CMP — SRP vs No SRP: OR 1.79 (95% CI 1.55, 2.08); P < 0.001; I2 = 84.7%

Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial

2026-11-04T12:17:30.458Z

Randomized controlled trial · Lancet Rheumatol, 2023. Mean change in pain intensity (11-point NRS), week 12: Low-dose naltrexone mean -1.3 (95% CI -1.7 to -0.8) points · Placebo mean -0.9 (95% CI -1.4 to -0.5)

A Randomized Controlled Neuroimaging Trial of Cognitive Behavioral Therapy for Fibromyalgia Pain

2026-11-04T12:15:39.533Z

Randomized controlled trial · Arthritis Rheumatol, 2023. Pain catastrophizing, post treatment — CBT vs EDU; P < 0.05; larger decreases with CBT

Reduced Cortico‐Cortical Resting‐State Connectivity in Sensory Systems Related to Bodily Pain in Juvenile Fibromyalgia

2026-11-04T12:15:39.533Z

Cross-sectional study · Arthritis Rheumatol, 2023. Voxel-wise rsFC alterations, JFM vs healthy: Reduced rsFC in paracentral lobule (PCL)/primary somatosensory cortex (S1), T = 4.89 pFWE < 0.001

Phenotypic characteristics of patients with chronic widespread pain and fibromyalgia: a cross-sectional cluster analysis

2026-11-04T09:23:05.516Z

Cross-sectional study · Scand J Rheumatol, 2024. Predictors of Cluster 1 assignment — Working: OR 66.67 (95% CI 7.14 to 500.00)

The Problem of Pain in Rheumatology: Variations in Case Definitions Derived From Chronic Pain Phenotyping Algorithms Using Electronic Health Records

2026-11-04T09:22:05.521Z

Cross-sectional study · J Rheumatol, 2023. Chronic pain prevalence: Analgesic medications 15% · Pain scores 18% · Pain diagnostic codes 21% · Pain interventions 22% · Quadrimodal 47% · Well-validated algorithm 37%

Come rain or shine: Is weather a risk factor for musculoskeletal pain? A systematic review with meta-analysis of case-crossover studies

2026-11-04T09:19:37.579Z

Meta-analysis · Semin Arthritis Rheum, 2024. No association between relative humidity, air pressure, temperature or precipitation and the risk of RA, knee pain or low back pain

Effects of exercise-based interventions on inflammatory markers in patients with fibromyalgia: A systematic review and meta-analysis

2026-11-04T09:19:37.579Z

Meta-analysis · Semin Arthritis Rheum, 2024. Pro-inflammatory biomarkers (19 comparisons) — EBIs: SMD 1.74 (95 % CI 0.85-2.62); p < 0.05; statistically significant decrease, especially IL8; low certainty